Together, these data suggest that the misregulation of p27kip protein, due to the genetic variants, can affect tumour suppressor function of CDKN1B. Therefore, the dysfunction of p27kip may lead to cancer development and/or may affect the outcome of anticancer therapies. Here, CDKN1B is linked to neoplasm.